Home › Blog › Regenexx Wins Second EHIR Award in as Many Years

Regenexx Wins Second EHIR Award in as Many Years

Published on Nov 3, 2020

Did you know that employers get together to find new ways to save money on healthcare? The main event in that world is called EHIR, which stands for the Employer Health Innovation Roundtable. Regenexx was awarded a lead innovator award last year and it just received its second such award this week. Let’s dig in.

What is EHIR?

Employer Health Innovation Roundtable is a coalition of the largest and most progressive employers who want to accelerate the adoption of innovation. Twice a year they run a “dating service” of sorts where Fortune 500 companies get matched with healthcare innovators trying to improve their employee healthcare while saving money. The companies hear pitches from healthcare innovators and then list their top choices.

Learn More About Regenexx^® Procedures

Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.

We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.

Which Companies Make Up EHIR?

ehir company list

The company list is above. As you can see there are many Fortune 500 companies including American Airlines, Apple, AT&T, BestBuy, Boeing, Cargill, Chevron, CocaCola, Comcast, Delta, Disney, Google, HP, Hyatt, Johnson & Johnson, Liberty Mutual, Medtronic, Microsoft, Nasdaq, Pepsi, Progressive, Prudential, StateFarm, Target, Tesla, Home Depot, Travellers, United, Walmart, and Xcel Energy.

The EHIR Traction Award

The top innovators at EHIR that get matched with the most companies get a “Traction Award”. Regenexx got a traction award in 2019 and just got another one:

Regenexx had the highest number of matches in EHIR history last year and also has a high number of interested companies this year.

What is Regenexx Pitching to Employers?

Regenexx is signing up employers who want to reduce their orthopedic costs. Based on the data we have collected, we can save these companies large amounts of money and save their employees from invasive surgeries by moving them toward interventional orthobiologics. To learn more, see my video below:

The upshot? Regenexx continues to sign up large companies who want to both save money and reduce the number of surgeries needed by their employees. We also continue to rock the EHIR competition because companies want to thread the needle between saving money and providing better healthcare.

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.